PATENT CLAIM ANALYSIS

Application Number: 15972972
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "093210"]

Abstract:
The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.

Claim (Index 21):
The method of  claim 20 , wherein the tumor antigen is selected from one or more of CD19, CD20, CD22, EGFRvIII, and IL3Ra.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 93.0
- Lexical Diversity: 1.81034
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15094674', '14567426', '14568195', '14680860', '14568569']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7744562532907481
- 35 USC 102 Novelty (BERT): 0.5465275826239447
- Combined Prediction Score: 0.7516633862240677
- Mean Citation Score: 397.723566
- Max Citation Score: 411.00613
- Similarity Product: 310.319964293158

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test